Innoventric, which is manufacturing a device to treat heart valve diseases, raised a $28.5 million Series B, CEO Amir Danino tells Axios exclusively.
Why it matters: In contrast to standard procedures, Innoventric's device can be implanted without using echocardiography or general anesthesia, cutting down on cost and time.
